News Press Releases

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of ZIOPHARM Oncology, Inc.

TCRT | July 18, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of ZIOPHARM Oncology, Inc.

Levi & Korsinsky announces it has commenced an investigation of ZIOPHARM Oncology, Inc. (“ZIOPHARM” or the “Company”) (NASDAQ: ZIOP) concerning possible violations of federal securities laws.

On July 14, 2016, ZIOPHARM disclosed that a brain cancer patient in an ongoing clinical trial died after being treated with the Company’s experimental gene therapy, Ad-RTS-hIL-12. According to ZIOPHARM, at the time of the release, they had not yet informed the FDA of the death. The Company also disclosed the death of two other patients, which the Company described as unrelated to the drug. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/ziopharm-oncology-ziop

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.